Compare CNOB & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNOB | ABCL |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 3.5B |
| IPO Year | 1995 | 2020 |
| Metric | CNOB | ABCL |
|---|---|---|
| Price | $32.19 | $10.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $31.25 | $8.40 |
| AVG Volume (30 Days) | 379.7K | ★ 9.0M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ 1.51 | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $42.85 | N/A |
| Revenue Next Year | $7.27 | $21.85 |
| P/E Ratio | $21.37 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $23.20 | $2.75 |
| 52 Week High | $34.14 | $12.15 |
| Indicator | CNOB | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 66.21 |
| Support Level | $31.36 | $3.38 |
| Resistance Level | $33.95 | N/A |
| Average True Range (ATR) | 0.52 | 0.90 |
| MACD | -0.13 | 0.23 |
| Stochastic Oscillator | 23.18 | 77.49 |
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets, and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental, and consumer wages.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.